TL;DR
- Company: New Life Pharma LLC, a drug manufacturer at 265 Livingston Street, Northvale, NJ.
- Date: Warning Letter 320-26-65 issued April 14, 2026 (MARCS-CMS 725661).
- Classification: CGMP / Unapproved New Drugs / Misbranded (sterile GLP-1 injectable drug products).
- Key citations: Semaglutide and tirzepatide multi-dose vials sold as unapproved new drugs (FD&C Act 505(a)) and misbranded for lacking registration and listing (502(o)); no aseptic process validation (211.113(b)); five separate quality-unit failures (211.22, tied to 211.100(a), 211.84(d)(1)-(d)(2), 211.167(a), 211.67(b), and 211.137(a)); and denial of FDA access to two rooms labeled "Area Not in Use" (501(j)).
- Consequence: A February 25, 2026 voluntary recall of the GLP-1 vials, an inadequate March 6, 2026 response, and an explicit FDA instruction: "you should not restart drug manufacturing at this facility."
| Company | Location | Letter # | Issued | Issuing Office | Inspection Dates | Classification |
|---|---|---|---|---|---|---|
| New Life Pharma LLC | 265 Livingston Street, Northvale, NJ 07647-1901 | 320-26-65 (MARCS-CMS 725661) | April 14, 2026 | CDER | February 3–13, 2026 | CGMP / Unapproved New Drugs / Misbranded |
Can FDA order a company to permanently stop manufacturing a drug it never approved in the first place? FDA Warning Letter 320-26-65, issued April 14, 2026, addressed to Director of Quality Assurance Arthur Leong, closes with exactly that instruction: "you should not restart drug manufacturing at this facility." It is a rare line in a CDER warning letter, and the inspection behind it explains why.
FDA investigators spent February 3 to February 13, 2026 inside New Life Pharma's facility at 265 Livingston Street in Northvale, New Jersey (FEI 3012113519). They found a compounding operation manufacturing sterile multi-dose vials of semaglutide and tirzepatide (the active ingredients behind Ozempic, Wegovy, Mounjaro, and Zepbound) without FDA approval, without the sterility controls an injectable drug requires, and, in two rooms, without letting inspectors in at all.
The letter, signed by Jill P. Furman, JD, Director of the Office of Compliance at CDER, lays out four categories of violation: unapproved new drugs, misbranding through registration and listing failures, CGMP nonconformance, and limiting the inspection itself.
What the inspector found, in order
Unapproved new drug status. Under section 201(g)(1) of the FD&C Act, semaglutide and tirzepatide qualify as "drugs" because they are intended to treat disease or affect body structure or function, a status New Life Pharma itself confirmed by registering as a drug manufacturer and listing a semaglutide injectable in FDA's system. FDA cited the products' composition (the same active ingredients used in approved weight-loss and type-2-diabetes drugs), their design as lyophilized powder in sterile multi-dose vials requiring reconstitution for injection, and their distribution to weight-loss clinics and cosmetic surgery practices, in some instances shipped with bacteriostatic water purchased online. Labels carried a National Drug Code, "Rx-only," and "Sterile Multi-Dose Vial; Refrigerate after reconstitution." FDA's records show no approved application for either product, making them unapproved new drugs under section 201(p) and their interstate distribution a violation of sections 301(d) and 505(a).
Misbranding through registration and listing failures. New Life Pharma's FDA drug registration lists its operation as "Contract manufacturing for human over-the-counter drug products produced under a monograph." The inspection found the firm manufactures no OTC monograph drugs at all, only unapproved prescription drugs, including the two GLP-1 vials. Separately, 21 CFR 207.41 requires every registrant to list each drug it manufactures for commercial distribution; New Life Pharma has no labeler codes and has listed zero drugs despite manufacturing for commercial sale. Both gaps are prohibited acts under section 301(p), and they render the drugs misbranded under section 502(o) because they were manufactured at an unregistered, unlisted establishment.
Sterile manufacturing controls that never existed
211.113(b), no aseptic process validation. New Life Pharma manufactured the semaglutide and tirzepatide vials without written procedures to prevent microbiological contamination of a product purporting to be sterile. FDA found no aseptic processing simulations (media fills), no airflow visualization or smoke studies, no cleaning validation, and no routine environmental monitoring program. The firm operated under purported ISO 8 conditions without data to support even that classification, let alone the ISO 5 standard aseptic operations require. FDA wrote that these gaps "demonstrate that your firm lacked the fundamental controls necessary to ensure the sterility of your drug products," warning that the failure "placed patients at serious risk of receiving non-sterile products, which could result in severe infections or other life-threatening complications."
211.22, quality control unit failure. FDA cited five breakdowns tied to the quality unit's core responsibility: no adequate written production and process-control procedures (211.100(a)); no testing of components for identity and conformity with specifications (211.84(d)(1) and (d)(2)); no laboratory testing to confirm batches purporting to be sterile and pyrogen-free actually were (211.167(a)); no written cleaning-and-maintenance procedures for equipment (211.67(b)); and no stability testing to support the labeled expiration dates on the products (211.137(a)). FDA's conclusion: the quality unit "did not fulfill its fundamental responsibility to ensure that your manufacturing operations comply with CGMP requirements."
The rooms marked "not in use"
During the inspection, investigators were denied access to two areas inside the manufacturing suite. Facility staff had labeled both "Area Not in Use" and said they lacked authority to let inspectors in; when pressed, the firm confirmed it was refusing access. FDA's response was direct: its inspection authority under section 704(a) of the FD&C Act extends to every area of a registered facility, and a label on a door does not narrow that authority. Because the firm "delayed, denied, limited, and/or refused to permit" the inspection, the drugs manufactured there are adulterated under section 501(j), independent of the CGMP findings above.
Why FDA rejected the response
New Life Pharma moved on some fronts. After an FDA teleconference on February 19, 2026 recommending removal of distributed GLP-1 batches from the U.S. market, the company issued a voluntary recall of its semaglutide and tirzepatide vials on February 25, 2026, citing a "lack of assurance of sterility," posted as three separate listings on FDA's Enforcement Report website. On February 20, 2026, the firm also committed to ceasing production at the facility entirely.
That commitment did not hold. In its March 6, 2026 response to the Form FDA 483, New Life Pharma said production had only been paused, pending completion of media-fill validation studies, language signaling an intent to resume once the studies were done. FDA found the response inadequate on every count: no adequate evidence of corrective action, and nothing to give the agency confidence the firm could manufacture sterile drugs going forward. FDA wrote plainly: "Drug manufacturers labeling their product as sterile must recognize the serious public health implications of distributing a non-sterile product as it poses a significant health risk to patients." Given that none of the firm's drugs were approved and its sterile systems were, in FDA's words, "wholly lacking," the agency told New Life Pharma it should not restart production at the facility and asked for written confirmation that it would not manufacture drugs there in the future.
What this means for other GLP-1 compounders
Semaglutide and tirzepatide compounding has drawn sustained FDA attention as clinics and compounders moved to meet demand for GLP-1 products. This letter treats three failure modes as independently sufficient for enforcement: selling a compounded GLP-1 as though it were approved, running a sterile injectable line without the validation that line requires, and restricting an inspector's access to part of the facility. Any one of the three supports adulteration or misbranding on its own.
For compliance officers at facilities producing injectable GLP-1 products, the registration mismatch here is worth checking independently: a facility registered for one category of manufacturing while actually producing something else is a discrete violation, checkable without touching the production floor. And a "not in use" label offers no protection — FDA's inspection authority reaches every room in a registered facility, occupied or not.
FAQ
What did FDA's warning letter to New Life Pharma cite?
Unapproved new drugs (semaglutide and tirzepatide sterile multi-dose vials), misbranding through registration and listing failures, CGMP nonconformance under 21 CFR 211.113(b) and 211.22, and limiting the inspection by denying access to two rooms — all in Warning Letter 320-26-65, issued April 14, 2026.
Why are New Life Pharma's semaglutide and tirzepatide vials considered unapproved new drugs?
Semaglutide and tirzepatide are the active ingredients in FDA-approved drugs including Ozempic, Wegovy, Mounjaro, and Zepbound, but FDA's records show no approved application for New Life Pharma's own versions. Not being generally recognized as safe and effective for their labeled uses, and lacking FDA approval, they qualify as unapproved new drugs under section 201(p) of the FD&C Act.
What happened to the GLP-1 vials that were already in distribution?
After an FDA teleconference on February 19, 2026, New Life Pharma issued a voluntary recall of its semaglutide and tirzepatide vials on February 25, 2026, citing a lack of assurance of sterility. The recalls appear as three separate listings on FDA's Enforcement Report website.
Can FDA order a company not to restart drug manufacturing?
FDA's letter told New Life Pharma directly that it "should not restart drug manufacturing" at the Northvale facility and asked for written confirmation it would not manufacture drugs there in the future, given that none of its products were approved and its sterile systems were, in the agency's words, "wholly lacking." A warning letter is not itself a shutdown order, but it places the company on notice that continued manufacturing would compound the violations already on record.
Source: FDA Warning Letter 320-26-65, April 14, 2026. Byline: The Argus Regulatory Analysis Team. Published 2026-07-11.